S
Scott R. Solomon
Researcher at Northside Hospital
Publications - 139
Citations - 5567
Scott R. Solomon is an academic researcher from Northside Hospital. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 28, co-authored 139 publications receiving 3954 citations. Previous affiliations of Scott R. Solomon include National Institutes of Health & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S. Abramson,M. Lia Palomba,Leo I. Gordon,Matthew A. Lunning,Michael Wang,Jon E. Arnason,Amitkumar Mehta,Enkhtsetseg Purev,David G. Maloney,Charalambos Andreadis,Alison R. Sehgal,Scott R. Solomon,Nilanjan Ghosh,Tina Albertson,Jacob Garcia,Ana Kostic,Mary Mallaney,Ken Ogasawara,Kathryn Newhall,Yeonhee Kim,Daniel Li,Tanya Siddiqi +21 more
TL;DR: Overall safety and activity of liso-cel did not differ by dose level, with a high objective response rate, and a low incidence of grade 3 or worse cytokine release syndrome and neurological events in patients with relapsed or refractory large B-cell lymphomas.
Journal ArticleDOI
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet,Geoffrey L. Uy,Jorge E. Cortes,Laura F. Newell,Tara L. Lin,Ellen K. Ritchie,Robert K. Stuart,Stephen A. Strickland,Donna E. Hogge,Scott R. Solomon,Richard Stone,Dale L. Bixby,Jonathan E. Kolitz,Gary J. Schiller,Matthew J. Wieduwilt,Daniel H. Ryan,Antje Hoering,Kamalika Banerjee,Michael Chiarella,Arthur C. Louie,Bruno C. Medeiros +20 more
TL;DR: CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults with newly diagnosed sAML, and improved outcomes were observed across age-groups and AML subtypes.
Journal ArticleDOI
T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation
Asad Bashey,Xu Zhang,Connie A. Sizemore,Karen Manion,Stacey Brown,H. Kent Holland,Lawrence E. Morris,Scott R. Solomon +7 more
TL;DR: Haploidentical transplants performed using T-cell-replete grafts and post-transplantation cyclophosphamide achieves outcomes equivalent to those of contemporaneous transplantation performed using MRDs and MUDs, indicating such transplantation represents a valid alternative for patients who lack a conventional donor.
Journal ArticleDOI
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
Asad Bashey,Asad Bashey,Bridget Medina,Sue Corringham,Mildred Pasek,Ewa Carrier,Linda Vrooman,Israel Lowy,Scott R. Solomon,Lawrence E. Morris,H. Kent Holland,James R. Mason,Edwin P. Alyea,Robert J. Soiffer,Edward D. Ball +14 more
TL;DR: Ipilimumab, as administered in this clinical trial, does not induce or exacerbate clinical GVHD, but may cause organ-specific IAE and regression of malignancy.
Journal ArticleDOI
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
Jeffrey E. Lancet,Jorge E. Cortes,Donna E. Hogge,Martin S. Tallman,Tibor Kovacsovics,Lloyd E. Damon,Rami S. Komrokji,Scott R. Solomon,Jonathan E. Kolitz,Maureen Cooper,Andrew M. Yeager,Arthur C. Louie,Eric J. Feldman +12 more
TL;DR: A clinical benefit with CPX-351 is suggested, particularly among patients with secondary acute myeloid leukemia, and the rationale for a phase 3 trial currently underway in newly diagnosed secondary AML patients is provided.